Pymm et al., 2021 - Google Patents
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect micePymm et al., 2021
View PDF- Document ID
- 13776999695429310657
- Author
- Pymm P
- Adair A
- Chan L
- Cooney J
- Mordant F
- Allison C
- Lopez E
- Haycroft E
- O’Neill M
- Tan L
- Dietrich M
- Drew D
- Doerflinger M
- Dengler M
- Scott N
- Wheatley A
- Gherardin N
- Venugopal H
- Cromer D
- Davenport M
- Pickering R
- Godfrey D
- Purcell D
- Kent S
- Chung A
- Subbarao K
- Pellegrini M
- Glukhova A
- Tham W
- Publication year
- Publication venue
- Proceedings of the National Academy of Sciences
External Links
Snippet
Neutralizing antibodies are important for immunity against SARS-CoV-2 and as therapeutics for the prevention and treatment of COVID-19. Here, we identified high-affinity nanobodies from alpacas immunized with coronavirus spike and receptor-binding domains (RBD) that …
- 241001678559 COVID-19 virus 0 title abstract description 131
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pymm et al. | Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice | |
| Dacon et al. | Broadly neutralizing antibodies target the coronavirus fusion peptide | |
| Tortorici et al. | Broad sarbecovirus neutralization by a human monoclonal antibody | |
| Koenig et al. | Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape | |
| Sauer et al. | Structural basis for broad coronavirus neutralization | |
| Li et al. | High potency of a bivalent human VH domain in SARS-CoV-2 animal models | |
| Lv et al. | Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | |
| Liu et al. | The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants | |
| Wang et al. | A human bi-specific antibody against Zika virus with high therapeutic potential | |
| Bianchini et al. | Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein | |
| Mannar et al. | SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization | |
| Zhou et al. | Structural basis of Chikungunya virus inhibition by monoclonal antibodies | |
| Vogt et al. | Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease | |
| Bangaru et al. | Structural mapping of antibody landscapes to human betacoronavirus spike proteins | |
| Chen et al. | Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor | |
| Mousa et al. | Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein | |
| Dacon et al. | Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses | |
| Torres et al. | Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody | |
| Rouet et al. | Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies | |
| Zhang et al. | Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion | |
| Wang et al. | Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes | |
| Wu et al. | Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants | |
| Shi et al. | Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability | |
| Bullen et al. | Cross-reactive SARS-CoV-2 neutralizing antibodies from deep mining of early patient responses | |
| Ma et al. | Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD |